Latest close: back above its 200-day averageSep 8, 2026what changed →3/10Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
Price
$5.53+81%1Y
1M-4.8%1Y+81%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageValue58
Quality10
Momentum56
Growth-
What they do
Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we,” “our” or “us”) is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, molgramostim inhalation solution ("MOLBREEVI" or "molgramostim"), is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”).
In the company’s own words · 10-K filed Mar 13, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$1.24B
1Y Return+81%
5Y Return+350%
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.